BIO-Europe Spring EBD Group BIO Image Map
Share:
Email this page Share this on LinkedIn Share this on Twitter | print this page

BIO-Europe Spring® 2015 Program Overview

www.ebdgroup.com/bes/program
Sunday, March 8, 2015
19:00–21:30
Welcome Reception

All BIO-Europe Spring attendees are cordially invited to join us for a welcome reception.

You will be able to pick up your name badge at the welcome reception.

IMAGINE Institut

IMAGINE Institut des Maladies Génétiques
24, boulevard de Montparnasse
75015 Paris
France | (map)

The IMAGINE Scientific Cooperation Foundation was created in 2007 as a new type of research and innovative healthcare institute, bringing together researchers, doctors and patients with a common goal: to cure genetic diseases.

The Institute is housed in a brand-new 19,000 square meter building located on the campus of the Necker Enfants Malades Hospital. Over 850 researchers, doctors and healthcare personnel work to gather all those concerned in the treatment of genetic diseases, creating synergy that encourages transfer of knowledge to speed up the discovery of new treatments and diagnoses to meet the expectations of patients and their families.

The welcome reception will take place in the impressive atrium, generously provided by IMAGINE.

IMAGINE Institut des Maladies Génétiques IMAGINE Institut des Maladies Génétiques
Monday, March 9, 2015
07:45
Level 0
Registration opens
07:45
Level 1, Exhibit Hall
Exhibition opens and Continental Breakfast
09:00–10:30
Parallel Workshops
Translational medicine: From discovery to early stage drug development

Monday, 09:00–10:30
Level 0, Room D

Drug development from discovery to clinical applicability involves the collaborative efforts of academia, medical institutions and industry. While all three partners fully acknowledge and benefit in many ways from such cross-fertilization, strategies to create an appropriate environment for translational medicine, leading to synergy among partners, are essential and critical to its success. The panelists will share their experience in the challenges of translational medicine in respect to academic, clinical and industrial approaches and in the increasing demand for personalized medicine.

Moderator:
Shosh Merchav – CEO, Multifacet BioSolutions Ltd.

Panelists:
  • François Ballet – Chairman of the Board, Institute of Cardiometabolism and Nutrition (ICAN)
  • Marc Bonnefoi – VP, R&D France, Sanofi
  • Manuel Gea – CEO and VP R&D IS, Bio-Modeling Systems: Mechanisms-Based Medicine
  • Kurt Hertogs – Platform Innovation and Incubator Strategy Leader, Johnson & Johnson Innovation, London
BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Is nano becoming the next sweet spot for drug development?

Monday, 09:00–10:30
Level 0, Room B

Nanomedicine is now ubiquitously present with an increasing number of companies using nanotechnology that may provide new tools for physicians and ultimately change disease treatments. Nanomedicine players are globally represented by two complementary organizations: the European Technology Platform for Nanomedicine (ETPN) in Europe and the Nanomedicines Alliance in the US. Both organizations have witnessed the maturation of nanomedicine as more and more clinical data becomes available, an increasing number of registered studies and authorized products translating into more nano-therapeutic deals. The panelists will discuss whether and how this maturation will progress and the impact on development in the global pharmaceutical industry.

Moderator:
Laurent Levy – CEO, Nanobiotix; Vice-Chairman, ETPN

Panelists:
  • Sergio Capancioni – New Opportunities Officer, North America, Business Development and Licensing, Debiopharm International
  • Thomas Croisier – Partner, Monitor Deloitte
  • Henry Havel – Past Chair, Nanomedicine Alliance
BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Reimbursement in European markets

Monday, 09:00–10:30
Level 0, Room C

Reimbursement regimes in the US and key European markets continue to evolve and "innovate." This includes new and greater use of health technology assessment and related measures ostensibly designed to focus on ensuring that new products are rewarded only insofar as they provide additional therapeutic value. This panel explores both whether changing systems are really working that way, and the growing sharing of experience between payers and value assessment agencies in key markets, including the United States. It will also explore the additional burdens these systems are putting on developers of new products to demonstrate "value."

Moderator:
Alexander Natz – Secretary General, EUCOPE

Panelists:
  • Miriam Gargesi – Director, Healthcare Biotechnology, EuropaBio
  • Robin Kenselaar – VP, Europe, Middle East, Africa, Genzyme
  • David Talbot – Senior Director, International Government Affairs, Lilly
BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Vaccines for infectious diseases

Monday, 09:00–10:30
Level 0, Room E

The recent Ebola virus outbreak in West Africa took the public health community by surprise. However, it also has helped to galvanize and focus the infectious disease community on public-private partnerships that will help bring new vaccines to meet unmet medical needs around the globe. Vaccines using novel technologies are currently under development for important tropical diseases, such as dengue fever, hospital-acquired infections, and growing concerns like respiratory syncytial virus (RSV). This prestigious group of industry leaders will discuss the research and development strategies and business opportunities of new vaccines and how strong global partnerships can help prevent existing and emerging infections.

Moderator:
Phyllis Arthur – Senior Director, Vaccines, Immunotherapeutics and Diagnostics Policy, Biotechnology Industry Organization (BIO)

Panelists:
  • Pierre D'Epenoux – Executive VP, Chief Strategy Officer and Head of Business Development, Theravectys
  • Bruno Guy – Associate Director, Dengue Scientific Affairs, R&D, Sanofi Pasteur
  • Russell P. "Rip" Wilson – Senior VP, Business Development, Novavax, Inc.
BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
10:45–12:30
Level 0, Room A
Welcome and Plenary Session
Welcome
Opening remarks

Monday, 10:45–11:15
Level 0, Room A

Speakers:
  • Anna Chrisman – Group Managing Director, EBD Group
  • Arnaud Gobet – President, Medicen
  • Jean-Paul Planchou – VP, Regional Council (Economic Development, Innovation, Information Technology, Tourism and Social Economy), Ile de France
  • David Thomas – Director of Investment and Policy Research, Biotechnology Industry Organization (BIO)
BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Keynote Address
Speaker:
Serge Weinberg Serge Weinberg
Chairman of the Board
and CEO
Sanofi

Opening Plenary Session
Getting real: Biopharma innovation and its impact on patients

Monday, 11:15–12:30
Level 0, Room A

Leading biopharma executives will discuss their corporate strategies for innovative product development in an environment that focuses on pricing and reimbursement now more than ever before. How can companies focus on the important business of fulfilling unmet medical needs while demonstrating value to investors and payers? We will address their efforts in developing cures for rare diseases and chronic medical conditions, and highlight the changes in the overall healthcare market, the reimbursement landscape, patient engagement, and other significant factors impacting the industry today.

BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Moderator:
Antoine Papiernik Antoine Papiernik
Managing Partner
Sofinnova Partners

Speakers:
Pierre-Henri Benhamou Jakob Dupont Maya Said Joseph Truitt
Pierre-Henri
Benhamou

Co-Founder,
Chairman and CEO
DBV Technologies
Jakob Dupont
Senior VP, Chief Medical Officer, OncoMed Pharmaceuticals, Inc.; Adjunct Clinical Faculty, Department of Medicine, Stanford University Medical Center
Maya Said
VP, Head of Strategy, External Innovation & Science Policy Sanofi Global R&D
Joseph Truitt
Executive VP, Business Development and Chief Commercial Officer, Achillion Pharmaceuticals, Inc.
12:30–13:30
Level 0, Room A
Level 1, Exhibit Hall
Luncheon
13:30–18:15
Parallel Panel Discussions
Business Development
Blurred lines: Product development and manufacturing of biologics

Monday, 13:30–14:30
Level 0, Room B

By 2016, 45% of top 100 drugs sales will come from biologics. Production of biologics has specific and specialized requirements compared with small molecules. What are the strategies needed for the successful product development of biologics and what capabilities are required for long-term growth? This session will address these aspects of the development and production of biologics:

  • Importance of crossdivisional and crossfunctional collaboration for integrated and strategic development
  • Global infrastructure and partnering along the value chain of development and manufacturing
  • Challenges to manage increasing complexity of biologic formats while giving the patients global access to innovative treatments

Moderator:
Steve Dickman – CEO, CBT Advisors

Panelists:
  • Wolfram Carius – Senior VP, Biologics, Sanofi
  • Thierry Hulot – Executive VP, Head of Global Manufacturing and Supply, Member of the Pharmaceutical Executive Committee, Merck Serono
  • Alexander Jung – Senior Technology and Innovation Manager and BD Technologies, Boehringer Ingelheim
  • Weichang Zhou – VP, Biologics Process Development, WuXi AppTec Co., Ltd.
BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Major deal transactions

Monday, 14:45–15:45
Level 0, Room B

The panelists in this session examine some of the significant deals of the last 12 months, including transactions they have been involved in, and what these deals reveal about pharma's priorities, strategy and the options available to drug development companies in need of a corporate partner. Join dealmakers from these major companies for a strategic look inside the deal.

Moderator:
Mark Archer – Executive VP, Global Head of Business Development, inVentiv Health

Panelists:
  • Iain Dukes – Senior VP, Business Development and Licensing, MSD
  • Philippe Lopes-Fernandes – Senior VP, Head of Global Licensing and Business Development, Merck Serono
  • Kevin Sin – Senior Director, Business Development, Genentech
  • Pascal Touchon – VP, Scientific Cooperation and Business Development, Servier
BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Early stage financing strategies: The new colors of money

Monday, 16:00–17:00
Level 0, Room B

The record valuations that biotechs have achieved over the last two years have opened the floodgates of new investors that want a piece of the action. As a result many new vehicles are forming to fund early stage ideas, platforms, and product candidates. This panel will explore funding strategies and vehicles to help new companies get off the ground.

Moderator:
Douglas MacDougall – President, MacDougall Biomedical Communications

Panelists:
  • Fabrice Beauchene – Founder and CEO, My Pharma Company
  • Bernard Davitian – VP and Managing Director, Sanofi-Genzyme BioVentures
  • Sofia Ioannidou – Investment Director, Edmond de Rothschild Investment Partners
  • Thierry Laugel – Managing Partner, Kurma Partners
  • Erdem Yavuz – CFO and Co-Founder, myTomorrows.com
BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Due diligence: How to ensure a successful process

Monday, 17:15–18:15
Level 0, Room B

Moderator:
Martina Molsbergen – CEO, C14 Consulting Group

Panelists:
  • Chris Brown – Director, Scientific Licensing, Worldwide Business Development, GSK
  • Jan Case – Senior Director, Corporate Due Diligence, Shire
  • Ann Connolly – Senior Director, New Ventures, Johnson & Johnson Innovation, London
  • Carl Jessop – Due Diligence Director, AstraZeneca
BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Partnerships in Regenerative Medicine and Advanced Therapies


Partnerships in Regenerative Medicine and Advanced Therapies
Opportunities for regenerative medicine in Japan

Opportunities for regenerative medicine in Japan
Monday, 13:30–13:50
Level 0, Room D

Speaker:
  • Yoshihide Esaki – Director, Bio-Industry Division, Manufacturing Industries Bureau, Ministry of Economy, Trade and Industry (METI), Japan
BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Land of the Rising Sun: Also the land of opportunity for new business development

Land of the Rising Sun: Also the land of opportunity for new business development
Monday, 13:50–14:30
Level 0, Room D

This session will highlight the new initiatives and policies implemented to foster the growth of Japan's biopharma industry. Japan is currently the world's second largest economy and home to the largest aging population, and there are more opportunities than ever before for cross-border collaborations and investments. Panelists will provide insights on the advantages and keys to partnering with Japanese companies.

Moderator:
Christian L. Haller – CEO, The RavenOye Group

Panelists:
  • Vicki Anastasi – VP and Global Head, Medical Device and Diagnostics Research, ICON plc
  • William Hearl – President and CEO, Immunomic Therapeutics
  • Kunihiko Suzuki – Member of the Board, Chief Business Officer, MEDINET
  • Peter Virsik – Senior VP, Corporate Development, XenoPort
BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Cell-based immunotherapies for cancer: What types of partnerships will support successful commercialization?

Cell-based immunotherapies for cancer: What types of partnerships will support successful commercialization?
Monday, 14:45–15:45
Level 0, Room D

While the success of PD-1 inhibitors and other immunomodulators and their potential as combination treatments have led to a stampede by large pharma into cancer immunotherapies, there has been equally compelling news coming from the smaller group of companies focused on adoptive T-cell therapies and cell-based approaches. These types of therapies, most of them autologous, require a very different way of thinking about treatment and the types of partnerships needed to support successful commercialization. This panel will feature pharmaceutical companies that have decided to embrace this challenge as well as the perspective of smaller companies seeking partnerships that go beyond traditional back-ended, milestone-driven structures given the need of both parties to embrace risk and clinical challenges upfront.

Moderator:
Neill Mackenzie – CBO, Biotecnol Ltd.; Chairman, Cellular Therapeutics Ltd.

Panelists:
  • Robert Ang – Senior VP, Business Development, Bavarian Nordic
  • Georges Rawadi – VP, Business Development, Cardio3 Biosciences
  • Stephen Rubino – Global Head, Business Development and Licensing, Cell and Gene Therapy Unit, Novartis Pharmaceuticals Corporation
BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Gene therapy and genome editing: Addressing key considerations along the product development pathway

Gene therapy and genome editing: Addressing key considerations along the product development pathway
Monday, 16:00–17:00
Level 0, Room D

The renewed enthusiasm for gene therapy—in vivo and ex vivo and versatile genome editing technologies such as CRISPR/Cas-9 and Talen—have put the spotlight back on gene therapy. Large pharma and large-cap biotech are also jumping into the space with investments and partnerships focused on both monogenic disorders and ultra-orhpan indications that could be closer to the market as well broader market opportunities with much longer development timelines. Given that many of these opportunities will involve delivery technologies, or next-generation approaches to delivery as well as other key enabling platforms, we can expect to see an expanding number of deals with key technology developers as the field continues to mature. This panel will include the perspective of executives from some of the leading gene therapy companies in addition to key executives within large pharma who are working to position these new opportunities within their R&D pipelines.

Moderator:
Frédéric Revah – CEO, Genethon

Panelists:
  • Marina Cavazzana – Head of Department of Biotherapy, Hospital Necker Enfants, Malades (Paris)
  • Alexandra Glucksmann – Chief Operating Officer, Editas Medicine
  • Clark Pan – VP, Head of Discovery Therapeutics, Shire
BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Next generation treatments in ophthalmology: Can gene and cell-based therapies meet growing expectations for early clinical success?

Next generation treatments in ophthalmology: Can gene and cell-based therapies meet growing expectations for early clinical success?
Monday, 17:15–18:15
Level 0, Room D

Many experts predict that some of the early clinical successes in cell and gene therapy will be for ophthalmological indications such as retinitis pigmentosa, AMD, glaucoma, or some of the large number of orphan diseases of the eye where delivery and well-defined clinical outcomes are less of an issue. This panel will examine some of the latest developments related to the commercialization of new treatments for the eye and how these treatments are being positioned for clinical and commercial success.

Moderator:
Neil Canavan – Scientific Advisor, The Trout Group LLC

Panelists:
  • Jean-Philippe Combal – Chief Operating Officer, GenSight Biologics
  • Jose-Alain Sahel – Director, Institut de la Vision
  • Thomas F. Zioncheck – Senior Director, Business Development, Genentech
BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Therapeutic Insight 2014


Therapeutic Insight by Defined Health
Beyond HbA1c: Reducing cardiovascular complications in diabetes patients

Beyond HbA1c: Reducing cardiovascular complications in diabetes patients
Monday, 13:30–14:30
Level 0, Room C

The diabetes segment of the pharmaceutical market is continuing strong growth, fueled by demographics and innovation. However, higher regulatory hurdles, the need for CV outcomes studies, and threats from genericization and biosimilars place doubt on how long this trajectory can continue. There is no argument that the magnitude of morbidity, mortality and healthcare costs associated with Type 2 diabetes (T2DM) is one of the largest burdens on healthcare systems. Glycemic control remains an important objective, with metformin as a foundational therapy upon which novel drug classes (DPP-IV inhibitors, long-acting GLP-1s, insulin analogues, SGLT-2 inhibitors) are added. These new therapies have been approved in recent years based on reductions in HbA1c (regulatory surrogate marker) and non-inferior cardiovascular toxicity demonstrated in the shortest possible time. Although the availability of these new therapies allows better glucose-lowering strategies, few trials have yet to show unequivocal cardiovascular risk reduction with glucose lowering, even though most diabetic patients eventually die from cardiovascular causes, and cardiovascular events prompt the largest healthcare expenses. Accordingly, recent updates to guidelines for the management of T2DM include optimized glucose lowering to reduce the risk of microvascular disease, but further cardiovascular event reduction is recommended by vigilant blood pressure control via antihypertensives, and lipid reduction with potent statins for all diabetics above the age of 40 regardless of LDLc level. However, it is unclear how antidiabetic drug classes will prove additional cardiovascular event reduction on top of optimal cardioprevention, and there is concern that the diabetes pipeline is lacking sufficient investment to provide adequate innovative mechanisms to adequately feed pharma diabetes franchises in the future.

This panel will discuss the opportunities and challenges in reducing cardiovascular complications in diabetes patients and the development and commercialization of novel cardioprevention therapies.

Moderator:
Michael C. Rice – Senior Consultant, Defined Health

Panelists:
  • Peter Fenici – Global Medical Affairs, Senior Director, Diabetes, AstraZeneca
  • Jonas Hallén – Clinical Program Leader, R&D, Pronova BioPharma (now part of BASF)
  • Tomas Landh – VP, Senior Principal Scientist, R&D Innovation Sourcing, Novo Nordisk
  • George Szewczyk – Co-Founder, CEO and CSO, BioKier, Inc.
BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Neuroregenerative approaches for neurodegenerative diseases

Neuroregenerative approaches for neurodegenerative diseases
Monday, 14:45–15:45
Level 0, Room C

Currently available therapies for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, multiple sclerosis and amyotrophic lateral sclerosis range from moderately disease modifying to mildly symptomatic to nonexistent—all leaving significant unmet need. Neuroregenerative medicine, which aims to regenerate and restore a damaged nervous system, has to date been considered a potentially disruptive technology, but not yet sufficiently developed. Of late, however, important advances are being made, with several programs in clinical development. Paradigms being explored take several forms, including re-engineering a patient's stem cells to promote neural growth and methods aimed at counteracting inhibition of neural factors. Neuroregenerative methods are also being used to create disease models for these still largely ill-understood diseases by reprogramming adult stem cells from patients into pluripotent stem cells that can be differentiated into specific nerve cells affected by the disease.

Key questions/issues to be addressed on this panel discussion include:

  • What are the key near-term milestones/value inflection points that will support neuroregenerative medicine as a viable therapeutic approach?
  • Which organizations/companies are making real progress, with which types of approaches (e.g., neurotrophins and growth factors, stem cell therapy, gene therapy)?

Moderator:
Ginger S. Johnson – VP, Defined Health

Panelists:
  • Paul Blake – Chief Development Officer, Oxford BioMedica
  • Paul Gallagher – President, Compass Strategic Consulting
  • Peter Schueler – Senior VP, Global Medical and Safety Services, ICON
BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Revisiting underserved chronic conditions

Revisiting underserved chronic conditions
Monday, 16:00–17:00
Level 0, Room C

2014 marked the second highest year on record for the approval of new chemical entities; the 41 new drugs approved were topped only by the 53 recorded in 1996. Importantly for patients, a sizable majority of these new drugs such as Merck's Keytruda represent genuine breakthroughs. Others, such as Vimizim from BioMarin (for the ultra rare enzyme deficiency, Morquio A), represent hope for patients with previously neglected diseases. But of the new drugs approved last year, only slightly above one-third are for chronic diseases afflicting large populations (and most of these are "me-too" offerings for Type 2 diabetes). Conspicuous by their absence are any novel approaches to treat osteoarthritis, depression, urinary incontinence, osteoporosis and other widespread chronic conditions. Moreover, a dramatic misalignment exists within the industry's development pipeline between the number of candidates for comparatively small population diseases and those for more common and costly conditions. Striking example: Depression afflicts nearly as many people in the US as does cancer (and its economic costs are greater) but the pipeline shows <50 programs in the clinic in the US vs. nearly 1,500 in cancer (and a similar pipeline disconnect exists between cancer and arthritis, heart disease and stroke). Ironically, today's "neglected diseases" are precisely the ones that drove pharma's great success in the past.

Moderator:
Ed Saltzman – President, Defined Health

Panelists:
  • Iain Dukes – Senior VP, Business Development and Licensing, MSD
  • Anja König – Managing Director, Novartis Venture Fund
  • Nigel Sheail – Member of the Executive Committee and Head, Global Business Development and Licensing, Bayer HealthCare
  • Geoffrey A. Swire – VP, Business Development and Strategy, Radius Health
BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Undermining metastases and preventing recurrence: Therapeutics targeting cancer stem cells

Undermining metastases and preventing recurrence: Therapeutics targeting cancer stem cells
Monday, 17:15–18:15
Level 0, Room C

The inability to treat metastasis, the major source of mortality with most cancers continuing to be diagnosed late, is a key challenge in oncology. Various cells types have been proposed to account for the resilience that stymies therapy—both innate and acquired resistance, as well as genetic and epigenetic plasticity and hence heterogeneity. The idea common to most perspectives on metastases is that a hardy and stealthy subpopulation of cells exist—whether termed cancer stem cells (CSCs), dormant disseminated tumor cells (DTCs), or circulating tumor cells (CTCs), that may overlap completely or in part—that provide for the metastases. Numerous efforts have been underway to identify and define these cell types, and to develop specific therapeutics against them. For many in oncology, targeting such cells represents one of the Holy Grails of cancer, even in this age of immuno-oncology.

This panel will discuss the ideas underlying these unique cell populations, the various strategies being pursued to develop therapies against them, and the clinical development paths that may be different for these types of targets.

Moderator:
Jeffrey M. Bockman – VP, Defined Health

Panelists:
  • Jakob Dupont – Senior VP, Chief Medical Officer, OncoMed Pharmaceuticals, Inc.; Adjunct Clinical Faculty, Department of Medicine, Stanford University Medical Center
  • Hiroyuki Kouji – CEO, PRISM Pharma
  • Dan Paterson – Chief Operating Officer, Verastem
BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Pharma Presentations
13:45–14:00
Amgen

Amgen
Monday, 13:45–14:00
Level 0, Room E

Speaker:
  • Norbert Prenzel – Director, Business Development
BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
14:00–14:15
Pfizer

Pfizer
Monday, 14:00–14:15
Level 0, Room E

Speaker:
  • Max Mirza – Senior Director, External R&D Innovation
BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
14:15–14:30
AstraZeneca

AstraZeneca
Monday, 14:15–14:30
Level 0, Room E

Speaker:
  • Emma Barton – Evaluation Manager, Corporate Strategy and Development
BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Johnson & Johnson

Johnson & Johnson
Monday, 14:30–14:45
Level 0, Room E

Speaker:
  • Jeanne Bolger – VP, Venture Investments
BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
14:45–15:00
Roche

Roche
Monday, 14:45–15:00
Level 0, Room E

Speaker:
  • Oliver Froescheis – Interim Head Oncology, Roche Partnering
BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
15:00–15:15
Genentech

Genentech
Monday, 15:00–15:15
Level 0, Room E

Speaker:
  • Angele Maki – Senior Manager, Genentech Partnering
BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Bayer HealthCare

Bayer HealthCare
Monday, 15:15–15:30
Level 0, Room E

Speaker:
  • Nigel Sheail – Senior VP, Head of Business Development and Licensing
BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
15:30–15:45
Sanofi

Sanofi
Monday, 15:30–15:45
Level 0, Room E

Speaker:
  • Maya Said – VP, Head of Strategy, External Innovation and Science Policy, Sanofi Global R&D
BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Novartis Pharma

Novartis Pharma
Monday, 15:45–16:00
Level 0, Room E

Speaker:
  • Edward Wright – Business Development and Licensing Team
BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Takeda Pharmaceutical Company Ltd.

Takeda Pharmaceutical Company Ltd.
Monday, 16:00–16:15
Level 0, Room E

Speaker:
  • Jane Atkins – Global Licensing and Business Development; Director, Search and Evaluation
BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Merck Serono, a division of Merck KGaA

Merck Serono, a division of Merck KGaA
Monday, 16:15–16:30
Level 0, Room E

Speaker:
  • Philippe Lopes-Fernandes – Senior VP, Head of Global Licensing and Business Development
BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
16:30–16:45
MSD

MSD
Monday, 16:30–16:45
Level 0, Room E

Speaker:
  • Karen Akinsanya – AVP, Early Stage Assessment Business Development and Licensing
BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Shire Pharmaceuticals

Shire Pharmaceuticals
Monday, 16:45–17:00
Level 0, Room E

Speaker:
  • Naina Bhasin – Director, Business Development
BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
17:00–17:15
Novo Nordisk

Novo Nordisk
Monday, 17:00–17:15
Level 0, Room E

Speaker:
  • Tomas Landh – VP, Senior Principal Scientist, R&D Innovation Sourcing
BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
17:15–17:30
AbbVie

AbbVie
Monday, 17:15–17:30
Level 0, Room E

Speaker:
  • John Poulos – VP, Licensing and Acquisitions
BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Eli Lilly and Company

Eli Lilly and Company
Monday, 17:30–17:45
Level 0, Room E

Speaker:
  • M. Johnston Erwin – VP, Strategy and Operations, Corporate Business Development
BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
Alexion Pharmaceuticals

Alexion Pharmaceuticals
Monday, 17:45–18:00
Level 0, Room E

Speaker:
  • Susan Hill – Director, Business Development
BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
13:30–18:30
One-to-one Meetings ►
17:00–17:30
Level 1, Exhibit Hall
Exhibit Hall Wine and Cheese Reception

Hosted by the local French Host Sponsors at Booth 51:

Medicen Medicen
17:30–18:30
ICT for Health Monday Company Presentations

Monday, 17:30–18:30
Level 1, Exhibit Hall, Booth 51

March 9:
Ad Scientiam
Bioserenity
Electronic Alliance
Medusims
Withings

March 10:
Bodycap
Eeleo
Genious
Medclinik
NG Biotech

BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
18:00–18:45
Level 1, Exhibit Hall
Exhibit Hall Hospitality Reception

EBD Group Join us at booth 63.

Hosted by:

Dentons Dentons
19:00
Evening Networking Reception
Paris City Hall

Paris City Hall (Hotel de Ville)
3 rue de Lobau
75004 Paris, France

The Paris City Hall (Hotel de Ville) has been at the heart of political and social life in Paris since 1500. It is the largest City Hall in Europe, exerting influence over the 12 million people in the Paris region. The first Paris City Hall was built between 1523 and 1628 by French and Italian architects in the Renaissance style. Two and a half centuries later it was destroyed by fire during an uprising, but rebuilt from original designs between 1874 and 1882. Today the site is the center of cultural and sport activities like the giant Christmas crib, the winter ice skating rink, and the giant TV screen set up for the world soccer games in 1998.

Please note that all attendees must pass through a security check at the entrance to Hotel de Ville.

Sponsored by:

Sanofi Sanofi

Venue offered by:

Mairie de Paris Mairie de Paris

18:30–19:00 Shuttle buses depart from the conference center to the evening event.
21:30–22:30 Shuttle buses depart from the evening event to all conference hotels.

Tuesday, March 10, 2015
07:45
Level 0
Registration opens
07:45
Level 1, Exhibit Hall
Exhibition opens and Continental Breakfast
09:00–10:30
Academic Innovators™ Showcase

Tuesday, 09:00–10:30
Level 0, Room E

Join us for the Academic Innovators™ presentation track as we work with industry leaders to shine a spotlight on the many scientific advances with strong translational potential being made in the academic world.

Academic Innovators™ Presentations by:
AP-HP Tech Transfer
CEA
Cellspace
INSERM Transfert
Institut Pasteur
The Institut Carnot CALYM
The Institut Carnot Curie Cancer
The Institut Carnot Pasteur MI
The Institut Carnot Spine & Brain Institute (ICM)
The Institut Carnot Voir & Entendre

BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
08:00–18:30
One-to-one Meetings ►
09:00–10:30
Workshop
Innovative funding for SMEs in Europe

Tuesday, 09:00–10:30
Level 0, Room B

With the shortage of early stage life sciences funding, the role of government in funding the next generation of cures is becoming increasingly important. In January 2014, the European Union launched a multibillion euro funding program dedicated to all innovative small and medium sized enterprises (SMEs) in Europe. The session will provide an overview of this EU program as well as some other EU programs that are relevant for companies willing to strengthen their R&D pipeline.

The session will have three presentations. It will open with a presentation by a high-level representative from the EU (European Commission—DG Research and Innovation—Health Directorate) and will be followed by a testimony from an SME involved in EU projects which will share its experience in leveraging government funding to move their technology towards clinical adoption and commercialization. Finally, there will be a presentation with special focus on "How the European Commission promotes SMEs' internationalization process in research, innovation and trade" with support activities financed by the European Commission for the benefit of EU SMEs planning on entering into or expanding within Japan.

Speakers:
  • Mattias Bergqvist – Marketing Director, Biovica International
  • Rainer Henning – CEO, Biomay AG
  • Antoine Mialhe – Policy Officer, European Commission
  • Jessica Michelson – Marking and Communications Manager, EU-Japan Centre for Industrial Cooperation
BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
09:00–13:00
Company Presentations ►
10:45–11:15
Workshop
First-in-human: A critical step for biotechs in cancer drug development

Tuesday, 10:45–11:15
Level 0, Room B

Speaker:
  • Jean-Pierre Armand – Senior Oncologist, Expert in Phase I/II, Gustave Roussy Institute
BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
11:15–12:30
Workshop
Collaborative models for early clinical studies between innovative biotechs and academics

Collaborative models for early clinical studies between innovative biotechs and academics
Tuesday, 11:15–12:30
Level 0, Room B

Moderator:
Jean-Pierre Armand – Senior Oncologist, Expert in Phase I/II, Gustave Roussy Institute

Panelists:
  • Karen Akinsanya – AVP, Head of Early Stage Assessment, MSD
  • Øyvind K. Arnesen – CEO, Ultimovacs
  • Esteban Cvitkovic – Founder and CSO, OncoEthix
  • Filippo de Braud – Head, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale, Tumori, Milano
  • Vicenç Tur – CEO, Lipopharma
BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
13:00–14:00
Level 0, Room A
Level 1, Exhibit Hall
Luncheon
14:00–15:15
Workshop
ICT for Health

Tuesday, 14:00–15:15
Level 0, Room B

Moderator:
Nora Benhabiles – Program Manager, Health Sector, CEA List Institute; Director, Innovation, EIT Health

Panelists:
  • Franck Amalric – General Manager, Medusims
  • Milovan Stankov-Puges – CEO, NG Biotech
  • Emma Garde – Director, Customer Solutions and Innovation, Sanofi
  • Jean-Marc Bourez – eHealth Director, Department of Strategy, Development, Innovation, Business Excellence, Sanofi

Please note: Don't miss the ICT for Health start-up company presentations Monday and Tuesday from 17:30–18:30 at Booth 51.

BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
14:00–18:00
Company Presentations ►
15:30–16:30
Workshop
Rare disease, a patient-centric approach

Tuesday, 15:30–16:30
Level 0, Room B

Moderator:
Sylvain Forget – Founder and CEO, Nassyane; Co-Founder and COO, gmp-orphan

Panelists:
  • Anne Beal – Chief Patient Officer, Sanofi
  • Serge Braun – Scientific Director, Association Française contre les Myopathies - AFM
  • Luc-André Granier – CEO, Advicenne Pharma
  • Luigi Ravagnan – Head of External Relations and Partnerships, French Foundation for Rare Diseases
BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
17:30–18:30
ICT for Health Tuesday Company Presentations

Tuesday, 17:30–18:30
Level 1, Exhibit Hall, Booth 51

March 9:
Ad Scientiam
Bioserenity
Electronic Alliance
Medusims
Withings

March 10:
Bodycap
Eeleo
Genious
Medclinik
NG Biotech

BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
17:45–18:45
Level 1, Exhibit Hall
Exhibit Hall Hospitality Receptions

Hosted by:

Informa Informa
at Booth 65B
Lonza Lonza
at Booth 58
19:00
Evening Networking Reception
Salle Wagram – Eurosites

Salle Wagram – Eurosites
39–41 avenue de Wagram
75017 Paris, France | (map)

The Salle Wagram, located close to the famous Arc de Triomphe, is the city's oldest ballroom representing the high-class locales of the "Vie Parisienne." Although it was originally built in 1812, the Salle Wagram that we know today was rebuilt and inaugurated in 1865.

This historic building, once the favorite venue for Imperial parties, has held remarkable events throughout the years: 1st Cycle Fair, 1st French Boxing World Championship, Night of Jazz with Sidney Bechet and Louis Armstrong and the filming of famous movies. It is currently used to host receptions, parties, fashion shows, etc.

Sponsored by:

J&J Innovation J&J Innovation

18:30–19:00 Shuttle buses depart from the conference center to the evening event.
21:15–22:30 Shuttle buses depart from the evening event to all conference hotels.

Wednesday, March 11, 2015
07:45
Level 0
Registration opens
07:45
Level 1, Exhibit Hall
Exhibition opens and Continental Breakfast
09:00–11:15
Partnerships in Regenerative Medicine and Advanced Therapies

Partnerships in Regenerative Medicine and Advanced Therapies
Wednesday, 09:00–11:15
Level 0, Room C

Presentations by:
Gensight Biologics
Eyevensys SAS
Gene Signal SA
uniQure
Cytonet GmbH & Co. KG
Bone Therapeutics
Oxford BioMedica
Cellectar Biosciences, Inc.
Theravectys
Stemmatters
Sirona Biochem Corp.

BIO-Europe Spring® 2015
Share this:Email this pageShare this on LinkedInShare this on Twitter
08:00–17:00
One-to-one Meetings ►
13:00–14:00
Level 0, Room A
Level 1, Exhibit Hall
Luncheon
16:30
Level 1, Exhibit Hall
Closing Reception

Sponsored by the Host of BIO-Europe Spring 2016:

Stockholm The Capital of Scandinavia Stockholm The Capital of Scandinavia
at Booth 62
Arrow Up


© 2009–2015 EBD GmbH
BIO-Europe Spring EBD Group BIO Image Map